HOP homeobox (HOPX) is an unusual homeobox gene encoding three spliced transcript variants, among which the only HOPX-b promoter harbors CpG islands. The characteristics of its promoter methylation was analyzed using bisulfite sequencing and quantitative-methylationspecific polymerase chain reaction (Q-MSP), and the effects of HOPX expression were also examined. HOPX-b expression was silenced in all gastric cancer cell lines tested; its expression could be restored by treatment with demethylating agent. On Q-MSP, HOPX-b hypermethylation (cut-off value of 3.55) was found in 84% (67 out of 80) of primary tumor tissues and 10% (8 out of 80) of the corresponding normal tissues and could discriminate normal from tumor tissues (Po0.0001). The prognosis of the advanced cases with HOPX-b hypermethylation was as poor as those with stage IV disease when cut-off value was set at 11.28. This finding was validated in an independent cohort of 90 advanced gastric cancers. The HOPX-b hypermethylation was also an independent prognostic factor (P ¼ 0.029) on multivariate analysis. Exogenous HOPX expression significantly inhibited cell proliferation, colony formation and invasion as well as enhanced apoptosis. Taken together, HOPX-b promoter methylation is a frequent and cancer-specific event in gastric cancer. Quantitative assessment of HOPX-b methylation has great clinical potential as a marker of tumor aggressiveness.
Introduction
Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death worldwide (Crew and Neugut, 2006) . Recent improvements in diagnostic tools and methods have facilitated the detection of early gastric cancer. However, patients with advanced disease at the time of diagnosis remain poor outcomes. A growing number of DNA alterations in tumor-suppressor genes, especially gene promoter hypermethylation, are involved in the development and progression of gastric cancer. A better understanding of such methylation-related alterations may open the way to a host of innovative therapeutic strategies in gastric cancer.
HOP homeobox gene (HOPX, GenBank accession number NT 022853), also known as NECC1, LAGY or OB1, was initially identified as an essential gene for the modulation of cardiac growth and development (Chen et al., 2002) . Three spliced transcript variants, HOPX-a (NM 139212.2), HOPX-b (NM 139211.2) and HOPX-g (NM 032495.4), encode the same protein, which contains a putative homeodomain motif that acts as an adapter protein to mediate transcriptional repression (Kook et al., 2006) . HOPX expression is ubiquitous in diverse types of normal tissue, but not in various malignant tissues, including lung cancer, esophageal squamous cell carcinoma and uterine endometrial cancer (Chen et al., 2002 (Chen et al., , 2007 Yamashita et al., 2008; Yamaguchi et al., 2009) . The inactivation mechanism involves promoter methylation in esophageal squamous cell carcinoma and uterine endometrial cancer Yamaguchi et al., 2009) . Enforced HOPX expression inhibited tumor growth and RNA interference knockdown of endogenous HOPX restored it (Chen et al., 2007; Yamashita et al., 2008) . These findings suggest that the HOPX gene acts as a tumorsuppressor gene. However, the correlation between HOPX and gastric cancer remains unknown.
In this study, we examined the characteristics of HOPX-b promoter methylation in primary gastric cancer and assessed possibilities for using quantitative methylation status as a clinical applicable marker.
Results

HOPX-b promoter structure
The location of CpGs in the HOPX genomic sequence is shown in Figure 1a . Of the three spliced transcript variants, only HOPX-b promoter harbors CpG islands encompassing the first exon and intron, whereas the same promoter for HOPX-a and HOPX-g does not harbor any CpG islands. Therefore, the primers for bisulfite sequencing analysis were designed to amplify the promoter region for HOPX-b.
Characteristics of HOPX-b promoter methylation as compared with those of other genes associated with a high frequency of promoter methylation CDH4 (95%) (Miotto et al., 2004) , Integrina4 (85%) (Park et al., 2004) , KLF4 (80%) (Wei et al., 2005) , Reprimo (79%) (Takahashi et al., 2005) , Runx3 (45-71%) (Waki et al., 2003; Oshimo et al., 2004a) , PGP9.5 (50-73%) (Yamashita et al., 2006; Tokumaru et al., 2008) , RIZ1 (37-69%) (Tokumaru et al., 2003; Oshimo et al., 2004b) , XAF1 (69%) (Zou et al., 2006) , IGFBP3 (67%) (Tomii et al., 2007) and NMDAR2B (61%) (Liu et al., 2007) were the top 10 genes reported to have the highest frequencies of methylation in gastric cancer. We examined whether the frequency of HOPX-b methylation was comparable with those reported for such genes and whether HOPX-b methylation was a cancer-specific event in nine gastric cancer cell lines and the preliminary data set of 10 matched pairs (Supplementary Table 1) by bisulfite sequencing analysis (Figure 1b and Supplementary  Figure 1 ). Consistent with previous reports, CDH4, Integrina4, Reprimo and KLF4 showed methylation in more than 80% of tumor tissues. Among these genes, CDH4, Integrina4 and KLF4 showed methylation at almost the same frequencies in tumor tissues and the corresponding normal tissues, suggesting that methylation of these three genes is tissue-specific or associated with alterations in field cancerization (Ushijima, 2007) . On the other hand, HOPX-b showed methylation in 100% (9 out of 9) of gastric cell lines, 90% (9 out of 10) of tumor tissues and 10% (1 out of 10) of normal tissues, implying that HOPX-b promoter methylation may be the most frequent type of cancer-specific alteration, comparable with Reprimo methylation, among the methylated genes reported to date.
Next, quantitative-methylation specific polymerase chain reaction (Q-MSP) analysis was carried out; the maximum value of Q-MSP in samples that were unmethylated on the direct bisulfite sequencing was 3.55 ( Figure 1c) . To assess the relation between the values and methylation status of the individual CpG sites, we also carried out the bisulfite sequencing with cloned PCR products (Figure 1d) . The values below 3.55 showed only faint methylation in the examined 11 CpG sites, whereas the higher values showed a trend towards the denser methylation, and all gastric cell lines exhibited dense methylation. Thus, the cut-off value for aberrant methylation level of HOPX (that is, hypermethylation) may deem appropriate at 3.55 on Q-MSP (Supplementary Table 2) .
Transcriptional silencing by HOPX-b promoter methylation
The expression status of HOPX was evaluated by RT-PCR and western blotting (Figure 2a) . HOPX-b mRNA expression was not at a detectable level in any gastric cell lines and 4 of the 5 tumor tissues by RT-PCR and demonstrated the reduced level in tumor tissues compared with the corresponding normal tissues by quantitative-RT-PCR, consistent with the status of HOPX-b promoter methylation. It is interesting to note that the expression of either HOPX-a or HOPX-g was not at a detectable level in six gastric cell lines and two tumor tissues, regardless of the absence of CpG islands in the promoter region. Expression of any of these HOPX variants was consistently associated with HOPX-core expression. In addition, HOPX protein expression was also not detected in gastric cell lines and tumor tissues.
Subsequently, the cell lines were treated with demethylating agent 5-aza-2'-deoxycytidine (5-Aza-dC) alone, the histone deacetylase inhibitor Trichostatin A (TSA) alone, or the combination to examine the direct effect of HOPX-b promoter methylation (Figure 2b ). HOPX-b expression was restored in all gastric cell lines by any of the optimal conditions of demethylating agents, which was consistent with the restoration of HOPX-core. Expression of neither HOPX-a nor HOPX-g was restored by the demethylating agents. In addition, combined treatment with 5-Aza-dC and TSA upregulated HOPX-b expression to a greater extent than treatment with 5-Aza-dC alone or TSA alone in KatoIII and H111 cells. These findings suggest that HOPX-b promoter methylation is the most responsible for transcriptional silencing and that histone deacetylation may act synergistically in gene silencing in a subset of cell lines, as indicated in previous reports (Cameron et al., 1999; Liu et al., 2007) . Expression of both HOPXa and HOPX-g may be repressed by other mechanisms, such as mutations, deletions or regulation by upstream tumor-suppressive pathways.
Frequency and clinicopathological characteristics of HOPX-b promoter hypermethylation in primary gastric cancer To confirm the characteristics of HOPX-b hypermethylation in preliminary data set, Q-MSP analysis was HOP homeobox hypermethylation in gastric cancer A Ooki et al carried out using a cut-off value of 3.55, defined as hypermethylation by bisulfite sequencing analysis, in the data set of 80 matched pairs. HOPX-b hypermethylation was found in 84% (67 out of 80) of tumor tissues and in 10% (8 out of 80) of corresponding normal tissues, and this difference was significant (Po0.0001, Figure 3a ). In addition, the methylation values in tumor tissues were significantly higher than those in normal tissues, not only for each tumor stage (Po0.0001), but also in individual patients (Po0.0001). Neither the frequency of hypermethylation nor the methylation values in tumor tissues differed significantly according to tumor stage ( Figure 3b ). Subsequently, we used receiver-operating characteristic curves to evaluate whether the value of 3.55 was the optimal cut-off line for simultaneously maximizing both sensitivity and specificity in discriminating normal from tumor ( Figure 3c) ; the optimal cut-off value of 3.60 showed the sensitivity of 84% and specificity of 87%, and was almost similar to the value of 3.55. HOPX-b hypermethylation was associated with the vascular invasion (P ¼ 0.0025), but not with aging (Supplementary Table 3 ).
Immunohistochemical staining for HOPX was also carried out in the same set of 80 samples ( Figure 3d and Supplementary Figure 2) . The higher methylation values showed a significant trend towards the lower immunoreactive scores (P ¼ 0.0011, Supplementary Table 5 ).
Evaluation of HOPX-b promoter methylation as a marker of tumor aggressiveness, and univariate and multivariate prognostic analyses We investigated whether quantitative assessment of HOPX-b methylation could be used to predict patient prognosis and thereby serve as a marker of tumor aggressiveness. To calculate the optimal cut-off line for predicting prognosis, we investigated several cut-off values by log-rank prognostic analysis ( Figure 4a) . Methylation values from 6.64 to 15.21 were associated with significantly different 5-year disease specific survival between patients with higher methylation values and those with lower methylation values; a cut-off value of 11.28 showed the most significant difference (Po0.0001) and such methylation status in advanced gastric cancer was characteristic of stage IV disease from a prognostic point of view (Figure 4b). To exclude the possibility of over-fitting, we next analyzed in an independent data set of 90 consecutive patients with advanced cancer. Once again, HOPX-b methylation status with values above 11.28 showed significantly poor outcomes (P ¼ 0.009) and a characteristic of stage IV disease ( Figure 4c ). The cases with values above and below 11.28 were almost of the same frequency in stage IV disease, respectively (Supplementary Table 4 ). In addition, the Japanese Classification of Gastric Carcinoma staging system (P ¼ 0.0004) and HOPX-b methylation (P ¼ 0.029; Hazard ratio 1.79) showed the independent predictors of prognosis on the multivariate analysis (Table 1) .
Preoperative assessment of HOPX-b methylation status may improve the ability to evaluate tumor aggressiveness and thereby facilitate treatment planning.
Endoscopic biopsy is now a well-established procedure for gastric cancer and may enable the preoperative evaluation of methylation status in primary tumors. However, endoscopic biopsy specimens might not be representative of the whole tumor because of intratumor heterogeneity. It is therefore important to evaluate whether HOPX-b is homogenously methylated to the same extent in various regions of the primary tumor. We selected three tumor sections from whole primary tumors and examined methylation values in the superficial area, intermediate area and deepest area within these tumor sections, using a Leica Laser Microdissection System (Leica Microsystems, Wetzlar, Germany) to accurately obtain genomic DNA from each area. All three areas exhibited similar methylation values, indicating that HOPX-b methylation can be preoperatively analyzed in endoscopic biopsy samples (Figure 4d ).
To evaluate whether its expression status also could be an applicable marker of tumor aggressiveness, prognostic analysis was carried out as well. The immunoreactive scores in the cases with values above 11.28 were significantly lower than that in the cases with values below 11.28 (Po0.0001, Supplementary Table 5 ). HOPX expression status had significantly prognostic potential on a univariate analysis (P ¼ 0.0018), but not on a multivariate analysis, in which the Japanese Classification of Gastric Carcinoma staging system and HOPX-b methylation again showed the independent prognostic relevance (Supplementary Table 6 ).
Tumor suppressive activity after transfection of HOPX To gain insight into the potential role of HOPX as a tumor-suppressor gene in gastric cancer, GCIY cells were transfected with pcDNA 3.1-HOPX in which all the three spliced transcript variants (HOPX-a, HOPX-b and HOPX-g) were silenced ( Figure 2a ). Exogenous expression of HOPX was confirmed to be comparable with physiological expression level in human normal gastric mucosa by western blotting (Figure 5a ). The pcDNA 3.1-HOPX cells showed the remarkably decreased number of colonies by both anchorage-independent colony formation and colony focus assays and a less proliferative ability by WST-1 assay, compared with pcDNA 3.1-empty cells (Figure 5a and Supplementary Figure 3B ). Subsequently, cell-cycle assay was carried out to examine the role of HOPX in regulating cell growth (Figure 5b ). Cell-cycle distribution demonstrated the significantly increased sub-G1 population along with reduced G0/G1 population and minimally affected S and G2/M populations in pcDNA 3.1-HOPX cells compared with pcDNA 3.1-empty cells or mocktreatment cells, indicating that HOPX might suppress cell growth through induction of apoptosis but not cellcycle arrest. To further verify the result, apoptosis assay was carried out by Annexin V labeling and showed that both early and late apoptosis were significantly enhanced in pcDNA 3.1-HOPX cells compared with pcDNA 3.1-empty cells or mock-treatment cells (Figure 5c and Supplementary Figure 3C ). In addition, we found the suppression of invasion in pcDNA 3.1-HOPX cells (Figure 5d ). These similar results were obtained in AZ521 cells (data not shown).
Next, to reveal whether the expression levels can cause different aggressive phenotype even in an identical cell lines, we established stable clones with different (Supplementary Figure 4) . GCIY cells with weak expression (clone-H10) exhibited more aggressive abilities than those with strong expression (clone-H17). Whereas, AZ521 cells with nearly identical expression levels (clone-H3 and clone-H15) exhibited similar abilities. Moreover, TE15 cells that transfected with small interfering RNA (siRNA) against HOPX showed a trend toward more aggressive abilities (Supplementary Figure 5) .
Discussion
The assessment of promoter methylation may have four major clinical applications: neoplasm detection, studies of tumor biological behavior, prediction of treatment response and the development of therapies that target methylated tumor-suppressor gene (Esteller, 2003) . Here, we report that HOPX-b promoter methylation may contribute to the prediction of tumor behavior and therapy in gastric cancer. The frequency of HOPX-b methylation in primary tumor tissues were significantly higher than those in normal tissues and did not differ in tumor stage, indicating that HOPX-b methylation frequently occurs from an early stage in a cancer-specific manner. Moreover, the higher methylation values showed a significant trend toward the lower immunoreactive scores. HOPX-b expression was suppressed in line with promoter methylation status, and restored by demethylating agent treatment in gastric cancer cell lines. Taken together, these findings suggest that HOPX-b promoter methylation may be one of the predominant mechanisms for transcriptional silencing of HOPX.
HOPX-b methylation status in advanced gastric cancer was characteristic of stage IV disease from a Cancer-specific markers can be generally applied for the identification of cancer cells from body fluids from the patients; however, recent evidence demonstrated that aggressive markers have been largely reported from the primary tumor tissues, probably because primary tumor tissues include the most abundant molecular information of cancer cells (Sotiriou and Piccart, 2007; Yamashita and Watanabe, 2009 ). Hence, Q-MSP assay was applied from primary tumor tissues along the recent evidence. In current clinical practice, the most common prognostic parameter is the staging system, but the diverse prognosis even among identical stage reinforces the need for integrative models that combine staging system and molecular classification (Sotiriou and Piccart, 2007; Zhang and Fang, 2008) . Therefore, quantitative assessment of HOPX-b methylation, as a prognostic factor independent of staging system, may facilitate the development of therapeutic strategies in identical stage, for example, by helping to decide whether adjuvant chemotherapy is required to prevent recurrence even for patients with stage I disease, as well as those with stage II and III disease with the benefit of adjuvant chemotherapy (Sakuramoto et al., 2007) , or whether more potent chemotherapy should be used for patients with stage II and III disease who harbored the higher methylation. Moreover, preoperative assessment using endoscopic-biopsied specimens may lead to the use of staging laparoscopy to assess operability or neoadjuvant chemotherapy (Lowy et al., 1999; Lehnert et al., 2002) .
We also evaluated those assays, which could be more suitable to predict tumor aggressiveness, immunohistochemical staining for transcriptional product HOPX and Q-MSP for HOPX-b methylation leading to its transcriptional silencing, and showed that HOPX expression status was less accurate in predicting prognosis. Q-MSP for HOPX-b methylation may represent relative inhibition against innate volume of HOPX expression by transcriptional silencing in contrast to the immunohistochemical staining for evaluation of absolute volume of HOPX expression. It is possible that the relative inhibition may represent tumor aggressiveness more faithfully, whereas the meaning of absolute volume of HOPX expression may have different significance individually. Less accuracy of immunohistochemistry might also be affected by a number of critical factors, such as formalin-fixation artifacts, subjective interpretation, polyclonal antibody, scoring system, and presence of HOPX-a and HOPX-g that encode the same protein. The algorithm development to circumvent the subjective and equivocal interpretation of HOPX expression status including optimal protocols of tissue fixation and staining procedure were required to finally conclude the comparison of the methodologies. On the other hand, Q-MSP can achieve much more objective and specific assessment in a small amount of genomic DNA through PCR amplification using methylation-specific primers and fluorescent probe (Brena et al., 2006) . For these reasons, at present, we believe that quantitative assessment of HOPX-b methylation is the preferable method for tumor aggressiveness marker of advanced gastric cancer. Further research will be necessary to validate our findings.
HOPX has an important role in the normal development of tissues, such as the heart and the skeletal muscle (Chen et al., 2002; Kee et al., 2007) , whereas the molecular mechanism remains unclear in malignant disease. In normal tissues, HOPX lacks several key conserved homeodomain residues for binding to DNA, but it inhibits serum response factor-dependent transcriptional activation by recruiting histone deacetylase activity (Chen et al., 2002) . Thus, HOPX functions as an adaptor protein to regulate a delicate balance between proliferation and differentiation through negative-feedback regulation (Kook et al., 2006) . However, stable transfection of HOPX into esophageal squamous cell carcinoma cell lines does not necessarily repress serum response factor activity, and this activity does not correlate with tumorigenic potential, thus indicating that mechanisms other than serum response factor inactivation have important roles in tumorigenesis . Identifying the molecular mechanism of HOPX might provide important clues leading to new molecular therapeutic targets in gastric cancer.
In summary, we have demonstrated for the first time that HOPX acts as a new tumor suppressor and HOPXb promoter methylation, a frequent and cancer-specific event, is one of the predominant mechanisms for transcriptional silencing of HOPX in gastric cancer. We have also shown that quantitative assessment of HOPX-b promoter methylation could be an aggressive marker that may facilitate the development of therapeutic strategies for advanced gastric cancer.
Materials and methods
Cell lines and tissue samples
The gastric cancer cell line MKN7 was kindly provided from the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan). Eight other gastric cancer cell lines, GCIY, AZ521, KatoIII, SH10, H111, MKN74, NUGC4 and KE97, and the esophageal squamous cell carcinoma cell line TE15 (Nishihira et al., 1993) is used as an unmethylated cell line of HOPX-b, were purchased from RIKEN BioResource Center (Ibaraki, Japan). All cell lines were grown in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum.
Ten pairs of frozen primary gastric cancer tissue and corresponding normal mucosal tissue, obtained at least 5 cm from the tumor edge, were analyzed as the preliminary data set for the expression and methylation status. As analysis of genomic DNA samples at different stages of cancer progression can facilitate the identification of methylation markers for disease progression (Laird, 2003) , we also studied in 80 matched pairs of formalin-fixed, paraffin-embedded, tissue samples that were obtained from 20 randomly selected patients with each stage of the disease (stages I, II, III and IV) as defined in the staging system of the thirteenth edition of the Japanese Classification of Gastric Carcinoma (Japanese Gastric Cancer Association, 1998). Moreover, the relation between methylation status and poor prognosis shown in the data set of 80 patients was validated in the independent data set of 90 consecutive patients with advanced gastric cancer. All patients underwent gastrectomy according to the gastric cancer treatment guidelines in Japan (Nakajima, 2002) . Detailed information on 10, 80 and 90 patients in data sets is summarized in Supplementary Tables 1, 3 , and 4, respectively. We excluded patients who had any of the neo-adjuvant therapy or other primary malignancy. Advanced gastric cancer is defined as cancer invading the muscularis propria or deeper, irrespective of presence or absence of lymph node metastases (Japanese Gastric Cancer Association, 1998). All tissue samples were collected at the Kitasato University Hospital, and informed consent was obtained from all patients and healthy donors before sample collection. This study was approved by the Ethics Committee of Kitasato University.
Bisulfite treatment of DNA and sequencing analysis Tissue sections from tumor and the corresponding normal mucosa were sharply dissected on hematoxylin and eosinstained slides, and genomic DNA was subsequently extracted using of a QIAamp DNA FFPE Kit (Qiagen Sciences, Hilden, Germany). Genomic DNA from cell lines and frozen tissues were extracted using a QIAamp DNA Mini Kit (Qiagen). Bisulfite treatment was carried out using an EpiTect bisulfite kit (Qiagen) and was subsequently amplified by PCR. Primer sequences for the genes of interest were designed to recognize DNA alterations caused by bisulfite treatment (Supplementary Table 7 ). The PCR products were sequenced using a Big Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). Methylation of more than 50% in total CpGs or the presence of both methylated and unmethylated alleles was defined as positive methylation. In addition, for HOPX gene, PCR products were purified and then inserted into pCR 4-TOPO vector using a TOPO TA cloning kit for sequencing (Invitrogen, Carlsbad, CA, USA), selected 10 clones for each sample and then sequenced.
Q-MSP
To quantify the methylation level of HOPX-b, Q-MSP was carried out using iQ Supermix (Bio-Rad Laboratories, Hercules, CA, USA) in triplicate on the iCycler iQ real-time PCR detection system (Bio-Rad Laboratories). PCR condition and sequences of primer and probe are provided in Supplementary Table 8 . Serial dilutions of CpGenome universal methylated DNA (CHEMICON International, Temecula, CA, USA) were used to construct the calibration curve on each plate. CpGenome universal methylated DNA and unmethylated DNA (CHEMICON) were used as a methylation positive control and a negative control, respectively. The methylation value was defined by a ratio of HOPX-b normalized to b-actin and then multiplied by 100, according to the comparative cycle threshold method (Mandelker et al., 2005) .
RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen), and reverse-transcribed with a SuperScript III reverse transcriptase kit (Invitrogen). RT-PCR was carried for the three spliced variants and a common transcript core (HOPX-core) in HOPX (Supplementary Table 8 ). The PCR products were separated on 1.5% agarose gels and visualized by ethidium bromide staining. Quantitative-RT-PCR for HOPX-b or HOPX-core was carried out using iQ SYBR Green Supermix (Bio-Rad Laboratories) on the iCycler iQ real-time PCR detection system. Relative quantitative analysis normalized to b-actin was carried out according to the comparative cycle threshold method (Livak and Schmittgen 2001) .
Western blotting
Whole cells lysates were extracted in RIPA buffer (Pierce, Rockford, IL, USA) supplemented with 10 ml/ml Halt Protease Inhibitor Cocktail kit (Pierce) and Halt Phosphatase Inhibitor Cocktail kit (Pierce). The protein concentrations were determined using a Coomassie Plus-The Better Bradford Assay kit (Pierce), separated on NuPAGE 4-12% Bis-Tris Gel (Invitrogen). The anti-HOPX polyclonal antibody (dilution of 1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-b-actin monoclonal antibody (dilution of 1:10000, Sigma, St Louis, MO, USA) were used.
5-Aza-dC and TSA treatment Cells (1 Â 10 6 /T-75 flask) were treated with 1 or 5 mmol/l of the demethylating agent 5-Aza-dC (Sigma) dissolved in 50% acetic acid or were mock-treated with PBS including the same amount of acetic acid every 24 h for 5 days. When combined with the histone deacetylase inhibitor TSA (Sigma), 300 nmol/l TSA was added to the medium for the final 24 h (Mandelker et al., 2005) .
Immunohistochemistry
Immunohistochemistry was carried out using the anti-HOPX polyclonal antibody (dilution of 1:100), as described previously (Ooki et al., 2009) . As HOPX immunoreactive scoring algorithms had not been optimized and standardized, the expression status was assessed using a German scoring system (Supplementary Table 5 ) (Remmele and Stegner, 1987) . The threshold for differentiating between a final positive and negative staining was set at 4 (Remmele and Schicketanz, 1993) .
Plasmid transfection and siRNA transfection A full length cDNA of HOPX was isolated from TE 15 cells using PCR with primer sets; 5 0 -caccatgtcggcggagaccgcgagcgg-3 0 and 5 0 -gtctgtgacggatctgcactctg-3 0 . A plasmid expressing HOPX (pcDNA 3.1-HOPX) was obtained by cloning the PCR products into the pcDNA 3.1D/V5-His-TOPO vector using a pcDNA 3.1 Directional TOPO expression kit (Invitrogen). The sequence of the cloned HOPX cDNA was verified by sequencing analysis. Empty vector with self-ligation (pcDNA 3.1-empty) was used as a control. PcDNA 3.1-HOPX and pcDNA 3.1-empty were transfected into gastric cancer cell lines using Lipofectamine 2000 reagent (Invitrogen), respectively. Cells treated with Lipofectamine 2000 Reagent alone were used as the mock cells. We also transfected pcDNA 3.1D/V5-His/lacZ control vector containing the gene for b-galactosidase and detected higher transfection efficiencies using a b-Gal staining kit (Supplementary Figure 3A ). To verify expression of HOPX, western blotting was carried out 48 h after transfection. Stable clones with HOPX overexpression were established by G418 (Invitrogen) selection.
For siRNA transfection, cells (2 Â 10 5 ) were transfected with 1 mmol/l Accell SMARTpool, siRNA-HOPX (Thermo Fisher Scientific, Lafayette, CO, USA) mixed with Accell siRNA Delivery Media (Thermo Fisher Scientific) according to the Thermo Scientific Dharmacon Accell siRNA Delivery Protocol. The Accell Non-targeting Pool (siRNA-ctr) and Accell siRNA Delivery Media alone (siRNA-mock) were used as a control for non-sequence-specific effects and as a mocktreatment, respectively.
Colony focus and anchorage-independent colony formation assays For colony focus assay, cells (1 Â 10 5 per well) were selected with G418 in 6-well plates. Media was changed every 3 days, after 2 week, cells were fixed, stained with crystal violet solution and counted.
Anchorage-independent cell growth assay was carried out as described previously (Ooki et al., 2009) . Cells were fed weekly by overlying fresh soft-agar solution containing G418, and colonies were photographed after 2 weeks of incubation. Both experiments were carried out in triplicate.
Invasion and proliferation assays
The invasion assay was performed in the 24-well BD BioCoat Matrigel Invasion Chamber (BD Biosciences Discovery Labware, Bedford, MA, USA), as described previously (Ooki et al., 2009) . After incubation for 22 h, membrane of the upper chamber was fixed and stained by Diff-Quik reagent (Sysmex, Kobe, Japan). Cells that had invaded through the membrane were counted in four separated fields per well.
The effects of HOPX expression on cell proliferation and viability (2 Â 10 3 cells per well) were measured using Premix WST-1 Cell Proliferation Assay System (Takara Bio, Tokyo, Japan) in 96-well plates. Both experiments were carried out in triplicate.
Cell cycle and apoptosis assays Cell cycle and apoptosis assays were carried out using Guava PCA System (Guava Technologies, Hayward, CA, USA). For cell-cycle assay, cells (2 Â 10 5 ) were harvested 72 h after transfection, fixed in 75% ethanol and stained with propidium iodide (Guava cell-cycle reagent). For apoptosis assay, the harvested cells (1 Â 10 5 ) were stained with Annexin V and 7-AAD (Guava Nexin reagent) for discrimination of early and late apoptotic cells, respectively. Both experiments were carried out in triplicate and analyzed using CytoSoft 2.1.5 software (Guava Technologies).
Statistical analysis
Fisher's exact test, w 2 -test or the Mann-Whitney U-test was used to statistically analyze categorical variables, and Student's t-test was used to analyze continuous variables. For continuous variables, the data are expressed as mean±s.d. The Kaplan-Meier method was used to estimate cumulative survival rates, and differences in survival rates were assessed with the use of the log-rank test. Disease specific survival was measured from the date of surgery to the date of death or the last follow-up. Variables suggested to be prognostic factors on univariate analysis (Po0.05) were subjected to multivariate analysis using a Cox proportional-hazards regression model. Po0.05 was considered to indicate statistical significance. All statistical analyses were conducted with JMP 7.0 software (SAS Institute, Cary, NC, USA).
